Quantcast
The Name Of A Drug Significantly Influences How The Patient

The Name Of A Drug Significantly Influences How The Patient Feels About The Treatment

Rayshell Clapper for redOrbit.com - Your Universe Online Many individuals rely on pharmacology for different physical or mental health issues. However, some conditions require certain pharmacology which can be described as used for something...

Latest Antipsychotic Stories

2014-10-21 12:32:28

Ameritox's Ingenuity Health introduces method to help assess medication adherence in patients prescribed Risperdal® BALTIMORE, Oct. 21, 2014 /PRNewswire/ -- Ameritox(SM), the nation's leader in medication monitoring solutions, today launched a method to help assess medication adherence in behavioral health patients prescribed the antipsychotic drug risperidone (tradename, Risperdal(®)). This new method marks a critical step toward establishing a comprehensive reference database for...

2014-10-18 23:01:41

The Firm is representing numerous Risperdal lawsuit plaintiffs in claims that allege the atypical antipsychotic medication caused gynecomastia, or male breast growth. New York, New York (PRWEB) October 18, 2014 Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in a mass tort litigation now underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, 888 product liability claims have been filed in...

2014-10-15 12:31:56

NEW YORK, Oct. 15, 2014 /PRNewswire/ -- As Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) continue to mount in U.S. courts, a hearing recently held in Vermont is raising serious questions about the adherence to pediatric dosing guidelines by doctors who prescribe antipsychotic drugs like Risperdal to children, Bernstein Liebhard LLP reports. According to Dr. David C. Rettew, Director of the Pediatric Psychiatry Clinic at University of Vermont's College of Medicine, a...

2014-10-14 12:26:46

Sales of a Novel Antipsychotic and an Improved Rescue Therapy Will Contribute Approximately $1 Billion to the PD Market in 2023, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 14, 2014 /PRNewswire/ -- Decision Resources Group finds that the Parkinson's disease (PD) pharmacotherapy market will grow 5 percent annually from $2.3 billion in 2013 to $3.8 billion in 2023. This growth will be fueled by the launch of several emerging therapies--including new molecular...

2014-10-14 08:33:40

MIAMI and NEW YORK, Oct. 14, 2014 /PRNewswire/ -- Noven Pharmaceuticals, Inc., today announced the publication of data on the effects of low-dose mesylate salt of paroxetine (LDMP), marketed as Brisdelle(® )(paroxetine) capsules, 7.5 mg, in the October 2014 issue of Menopause, the peer-reviewed, scientific journal of The North American Menopause Society (NAMS). The article, "Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated...

2014-10-13 16:25:04

--Study Demonstrated Clinically Meaningful and Statistically Significant Improvement of Agitation in Patients with Alzheimer's Disease-- ALISO VIEJO, Calif., Oct. 13, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that results from the Phase II study evaluating AVP-923 for the treatment of agitation in patients with Alzheimer's disease were presented at the 2014 American Neurological Association Meeting. In this study utilizing the two-stage, sequential...

2014-10-13 08:26:39

WOODCLIFF LAKE, N.J. and SAN DIEGO, Oct. 13, 2014 /PRNewswire/ -- Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for BELVIQ® (lorcaserin HCl) CIV will be presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting taking place October 12-15, 2014, in Austin, Texas. BELVIQ is a serotonin 2C receptor agonist approved in the United States as an adjunct to a reduced-calorie diet and increased physical...

2014-10-11 23:03:48

Risperdal Lawsuit Claims Continue With Meeting Scheduled In October For Gynecomastia Lawsuits Pending Litigation Columbus, OH (PRWEB) October 11, 2014 As Risperdal lawsuit claims continue in the Philadelphia Court of Common Pleas, another monthly meeting has been scheduled for parties to discuss the litigation surrounding antipsychotic drugs and the development of male breasts or gynecomastia. According to court records there are nearly 80 Risperdal lawsuit claims pending in the...

2014-10-10 23:01:05

The Firm is representing numerous Risperdal lawsuit clients in the Pennsylvania litigation, all of whom allegedly developed gynecomastia, or male breast growth, due to their use of the atypical antipsychotic medication. New York, New York (PRWEB) October 10, 2014 Risperdal lawsuits (http://www.risperdallawsuitcenter.com/) that allege the atypical antipsychotic medication caused men and boys to develop gynecomastia (male breast growth) continue to move forward in a mass tort litigation now...

schizophrenia
2014-10-09 09:08:11

Rayshell Clapper for redOrbit.com - Your Universe Online Most people have been affected by mental illness either personally or through friends, family and loved ones. The National Alliance on Mental Illness estimates that one in four American adults suffer from mental illness a year. Of those, about one in 17 live with a serious mental illness such as schizophrenia, major depression or bipolar disorder. All mental illnesses are dangerous and can be debilitating, which is why awareness...


Word of the Day
negawatt
  • A unit of saved energy.
Coined by Amory Lovins, chairman of the Rocky Mountain Institute as a contraction of negative watt on the model of similar compounds like megawatt.